Pediatric Cancer
Case Study Suggests Use of Targeted Therapy, Surveillance for Germline ALK-Mutant Neuroblastoma
Premium
Two family members with a germline ALK-mutant neuroblastoma both experienced complete response to ALK inhibitors in a case study.
Leukemia & Lymphoma Society Expands Pediatric AML Trial to Include Kura Oncology's Menin Inhibitor
Premium
Leukemia patients who enroll in LLS's PedAL screening trial and are found to have certain alterations will be directed to receive ziftomenib in a Phase I study.
BrainChild's B7-H3 CAR T-Cell Therapy Will Advance to Registrational Phase II Trial in Late 2025
The treatment for aggressive pediatric brain tumors received breakthrough therapy designation from the FDA.
All children and adolescents with cancer in Ireland, including those who relapse following treatment, will be offered enrollment in the project.
Foundation Medicine Assay Nabs FDA Approval as CDx for Ojemda in Pediatric Patients
The FoundationOne test can be used to identify patients with relapsed or refractory BRAF-altered pediatric low-grade glioma who may be eligible for therapeutic options.